Johnson & Johnson reports 75% tumor response with JNJ-6143 in Phase 1 prostate cancer trial
Johnson & Johnson (NYSE:JNJ) presented Phase 1 results for JNJ-6143, an experimental oral treatment for advanced prostate cancer, at the ESMO 2026 congress in Madrid. In the 50 mg group, 12 of 16 patients with measurable disease achieved a confirmed tumor response (75%), and 77% of 38 patients recorded a PSA reduction of at least 50%. The company selected that once-daily dose to continue with a Phase 2 trial in metastatic cancer. The most frequent adverse events were elevated cholesterol, nausea and high triglycerides.
In 45 seconds
- In the 50 mg group, 12 of 16 patients with measurable disease achieved a confirmed complete or partial tumor response, a rate of 75%
- 77% of 38 patients on that dose had a confirmed PSA reduction of at least 50%, and 48% fell by 90% or more
- The most frequent adverse events were elevated cholesterol (18%), nausea (16%) and increased triglycerides (16%); one patient discontinued treatment
Read the full story at Revista ADVFN
IASummary generated by artificial intelligence from a story by Revista ADVFN. It may contain errors: the original source prevails.
Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.